Table 2.

The table compares the main endocrine variables between azoospermic and RE/FOE patients undergoing TESE, according to clinical category (cancer survivors vs. non-oncologic controls). While chemotherapy/radiotherapy causes an increase in FSH and a reduction in testosterone in azoospermic men, the effect in RE/FOE patients is less severe, affecting FSH values only

	Azoospermia with TESE +		p	RE/FOE group with TESE +		s
	Oncologic	Controls		Oncologic	Controls
No.	67	207		21	19
Age	37.3 ± 5.1	36.9 ± 5.6	0.864	39.1 ± 6.3	47.6 ± 10.2	0.006
FSH (mu/ml)	21.8 ± 14.2	22.0 ± 10.3	0.333	8.9 ± 6.4	4.7 ± 2.5	0.016
Testosterone (ng/dl)	384.3 ± 149.9	434.5 ± 160.1	0.027	492.8 ± 121.7	425.9 ± 280.6	0.111

RE/FOE = retrograde ejaculation/failure of emission